瑞科生物-B:2023年報
Recco Bio-B (02179) nominated Liu Yong as a candidate for the second board of directors
The term of directors of the second board of directors is three years. It takes effect from the date the relevant bill is reviewed and passed by the company's shareholders' meeting. At the end of their term of office, they can be re-elected.
Recobiotics and Rongsheng Biotech sign a strategic cooperation agreement on a novel adjuvant vaccine project
Taizhou, March 27, 2024/PRNewswire/ -- Recently, Jiangsu Ruike Biotechnology Co., Ltd. (hereinafter referred to as “Recobiology”, stock code: 02179.HK) and Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biotech”) successfully held a novel adjuvant vaccine R&D project signing and project launch meeting in Shanghai. At the meeting, the two sides signed a strategic cooperation agreement on the novel adjuvant vaccine project and discussed in depth the details of the project progress. Adjuvants are important components in vaccine development, and novel adjuvants have become the key to the success of innovative vaccine development. According to this section of the agreement
Jiangsu Recbio Technology Co., Ltd.'s (HKG:2179) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 15% Last Week
Key Insights Jiangsu Recbio Technology's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 6 shareholders own 51% o
Jiangsu Recbio Technology's Loss Narrows in 2023
Jiangsu Recbio Technology's (HKG:2179) attributable loss narrowed to 572 million yuan, or 1.19 yuan per share, in 2023, from 722.7 million yuan, or 1.52 yuan per share, in 2022, according to a Wednesd
Recobiotics Releases 2023 Annual Results Report and Recent Developments
Taizhou, Jiangsu Province, March 21, 2024/PRNewswire/ -- On March 20, innovative vaccine company Recobiology (02179.HK) released its 2023 annual results report and latest developments. Recobiology has always adhered to the vision and mission of “creating first-class vaccines to protect human health”, guided by the company's strategy, and has achieved the following milestones and progress in research and pipeline and business operations. Business Summary REC603-recombinant HPV nine-valent vaccine The recombinant nine-valent HPV vaccine REC603 is undergoing phase III clinical trials in China, and regular follow-up work is being carried out according to the clinical plan.
Recco Bio-B (02179) announced annual results, loss attributable to shareholders of 572 million yuan narrowed 20.86% year over year
Recco Bio-B (02179) announced its annual results for the year ended December 31, 2023. The group...
RECBIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND NO FURTHER EXTENSION OF VALIDITY PERIOD OF RESOLUTIONS ON ISSUANCE OF DOMESTIC SHARES FOR 2023
Ricoh Bio-B (02179.HK) plans to hold a board meeting on March 20 to consider and approve annual results
Gelonghui, March 8, 丨 Ricoh Bio-B (02179.HK) announced that the board of directors meeting will be held on March 20, 2024 (Wednesday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
Jiangsu Recbio Technology to Extend Validity Period of Share Sale
Jiangsu Recbio Technology (HKG:2179) intends to extend the validity period for the issuance of domestic shares to Apr. 12, 2024, as the company needs more time to complete the offering. The extension
Two years until commercialization, RicoBio-B (02179) has fallen into a liquidity trap
Currently, Ricoh Biotech's main projects are the HPV nine-valent vaccine and the herpes zoster vaccine. However, in these two projects, the company must not only compete with competitors, but also compete with itself. The market is concerned about whether the company can transition to the commercialization stage under greater cash flow pressure.
Ricoh Biotech appeared at the 14th China (Taizhou) International Pharmaceutical Fair
Taizhou, October 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) International Pharmaceutical Fair hosted by the China Chamber of International Commerce and hosted by the Taizhou Municipal People's Government and the Jiangsu Branch of the China Council for the Promotion of International Trade was successfully held in Taizhou China Pharmaceutical City. As an innovative vaccine company with independent research and development technology as the core driving force, Recbio (02179.HK) presented at booth C18 in Hall E1-2 with three technical platforms for novel adjuvants, protein engineering, immunization evaluation, and major product pipelines. Once exhibited, it attracted a large number of domestic and foreign pharmaceutical companies
RECBIO-B: 2023 Interim Report
Press Release: Jiangsu Recbio Technology Co., Ltd. Announced 2023 Interim Results Report and Latest Progress
TAIZHOU, China, Aug. 27, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023.
Ricoh Biotech Releases 2023 Interim Results Report and Recent Developments
Taizhou, August 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) released its 2023 interim results report and latest developments. The company has always upheld the mission of “creating first-class vaccines and protecting human health”. During the reporting period, we rapidly promoted product development and achieved the following milestones and progress in research pipelines and business operations. The recombinant HPV nine-valent vaccine REC603 main efficacy trial study is undergoing regular follow-up work in accordance with the clinical plan. The 18th month of visits has been completed, and the 24th month of observation is ongoing. This phase III clinical formula
RECBIO-B: UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
RECBIO-B: DATE OF BOARD MEETING
China Approves Recbio's Clinical Trial Application for Shingles Vaccine
China's medical products administrator accepted Jiangsu Recbio Technology's (HKG:2179) clinical trial application for its REC610 adjuvanted recombinant shingles vaccine, according to a Wednesday filin
New adjuvant recombinant herpes zoster vaccine REC610 Chinese clinical trial application accepted and overseas clinical progress
Taizhou, July 27, 2023 /PRNewswire/ -- Ricoh Biotech (02179.HK) is pleased to announce that it has recently received an acceptance notice (acceptance number: CXSL2300518) from the State Drug Administration to accept its self-developed application for the new adjuvant recombinant shingles vaccine REC610. If no negative or questionable comments are received from the Drug Review Center within 60 days from the date of acceptance, the Company may conduct clinical trials according to the submitted plan. The company plans to use a randomized, double-blind, parallel Shingrix control design to recruit 18 in China
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index
Jiangsu Recbio Technology (HKG:2179) was selected as a constituent of the Morgan Stanley Capital International China Small Cap Index, according to a filing on Wednesday. The inclusion takes effect on
No Data